BC Extra | Dec 3, 2015
Financial News

Kesios' series A brings L19M

Kesios Therapeutics Ltd. (London, U.K.) closed a L19 million ($28.5 million) series A round led by existing investor Imperial Innovations Group plc (LSE:IVO). New investors SV Life Sciences and Abingworth also participated. Chairman and newly...
BioCentury | Oct 20, 2014
Emerging Company Profile

Kesios: Reactivating apoptosis

Kesios Therapeutics Ltd. is targeting a downstream component of the NF-kappa B signaling pathway that is overexpressed in multiple myeloma cells with the aim of providing efficacy similar to other MM therapies, but with a...
Items per page:
1 - 2 of 2